| Ytd | 38.84% | |
| 1y | 7.43% |
| Open | 12.45 | Prev Close | 12.45 | Low | 12.39 | High | 12.45 | Mkt Cap | 735.98M |
| Vol | 9.48K | Avg Vol | 1.68M | EPS | 2.96 | P/E | 4.21 | Forward P/E | -22.00 |
| Beta | 0.85 | Short Ratio | 6.51 | Inst. Own | 54.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 12.29 | 200-d Avg | 10.11 | 1yr Est | 20.00 |
ZVRA News
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, o
HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the C
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed p
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Co
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Co
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Con
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of S
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Re
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has received an average recommendation of
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the
Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings pa
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the
It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus an
US stocks rise with Dow up over 300 points, S&P 500 and NASDAQ also gaining. Kohl's Corp sha
Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS
US stocks mixed, Dow down 0.1%, NASDAQ up 0.13%, S&P 500 down 0.08%. Materials sector up, utilit
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zev
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevr
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage bi
Retail investors are preparing for another busy week of earnings season with more than 1,600 compani